Richard J. Benjamin - 12 Mar 2026 Form 4 Insider Report for CERUS CORP (CERS)

Reporting relationship: Chief Medical Officer
Issuer ticker: CERS
Reported as of: 12 Mar 2026
Net transaction value: -$168,604
SEC form: 4
Accepted by SEC: 16 Mar 2026, 19:43:34 UTC
Prior SEC filing: 10 Mar 2026
Source filing: View source filing
Reporting owner signature: Richard J. Benjamin, by Chrystal N. Jensen, attorney-in-fact

Key filing fact

Richard J. Benjamin filed Form 4 for CERUS CORP (CERS) on 16 Mar 2026.

Key facts

This page summarizes Richard J. Benjamin's Form 4 filing for CERUS CORP (CERS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Mar 2026, 19:43.

Change

Previous filing in this sequence was filed on 10 Mar 2026.
Current net transaction value: -$168,604.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001296322 Primary reporting owner

Benjamin Richard J

Relationship: Chief Medical Officer
Address: C/O CERUS CORPORATION, 1220 CONCORD AVE SUITE 600, CONCORD
Signature: Richard J. Benjamin, by Chrystal N. Jensen, attorney-in-fact
Signature date: 16 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CERS transaction

Common Stock

Sale

Transaction value: $168,604
Shares: -101,740
Change %: -12%
Price: $1.66
Shares after: 777,361
Date: 12 Mar 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person.

Footnote F2

Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.73 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth.